Myoclonic Astatic Epilepsy: Fenfluramine Safety Study

We are monitoring the long-term safety of Fenfluramine as an add-on therapy for patients with Myoclonic Astatic Epilepsy. This study aims to ensure the treatment is safe and effective for managing seizures.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Fintepla
Fintepla is a medicine used to reduce seizures in people with certain severe forms of childhood epilepsy, like Dravet syndrome.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Fenfluramine Hydrochloride
Fenfluramine hydrochloride is a substance that helps reduce seizures in people with severe epilepsy, including Dravet syndrome.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Krankenhaus Mara gGmbH
Department for Epilepsy
Bielefeld, Germany
Universitaetsklinikum Schleswig-Holstein AöR
Department of Children and adolesce
Kiel, Germany
Schoen Klinik Vogtareuth SE & Co. KG
Department of Neuropaediatrics and Neurological Rehabilitation
Stephanskirchen, Germany
Sponsor: Universitaetsklinikum Schleswig-Holstein AöR
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.